Dendreon Corporation  

(Public, OTCMKTS:DNDNQ)   Watch this stock  
Find more results for NASDAQ:DNDN
- Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 5.45M
P/E     -
Div/yield     -
EPS -1.06
Shares 158.72M
Beta     -
Inst. own 39%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -30.18% -104.60%
Operating margin -11.93% -85.65%
EBITD margin - -54.78%
Return on average assets -25.12% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -


601 Union St Ste 4900
SEATTLE, WA 98101-3906
United States - Map
+1-206-2197815 (Phone)
+1-302-6555049 (Fax)

Website links


Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.